There is a specific window opening up for anyone who held Aquestive Therapeutics (NASDAQ: AQST) stock last year. Misryoum analysis indicates that investors who bought in between June 16, 2025, and January 8, 2026, are currently being alerted to a looming deadline. If you’re one of them, the court needs to hear from you by May 4, 2026, if you want to take a lead role in the ongoing litigation.
It’s the kind of news that makes you stop and look at your portfolio—or maybe just sigh at the desk. The lawsuit claims Aquestive wasn’t entirely clear about its New Drug Application for Anaphylm. Specifically, the complaint alleges they downplayed the tricky human factors involved in using their sublingual film, like how the actual packaging and labeling might trip people up during an emergency. The smell of stale office coffee is especially strong this morning, which doesn’t make these legal complexities any easier to digest.
The central issue here, according to Misryoum reporting, hinges on whether the company misled shareholders by keeping quiet about those usability hurdles. When the market finally caught wind of the reality, the stock price took a hit, and that’s where the damages—supposedly—come in. Investors are being reminded that they don’t *have* to do anything right now to participate in potential future recoveries, but serving as a lead plaintiff is a different beast entirely.
Choosing the right representation is the next logical step, though it’s a bit of a minefield. Misryoum editorial desk noted that there are plenty of firms advertising their services, but not all of them actually litigate these cases; some act more like brokers for bigger firms. It’s a messy process. If you want to move the court, you need to be sure about your counsel—or maybe you just want to sit back and stay an absent member. Actually, that’s a choice only you can make.
Keep in mind that no class has been certified yet. You’re not technically represented by anyone until you sign something, so there’s no rush to act today, but definitely mark that May 4th date down. The legal landscape is shifting, and for those impacted by the AQST slide, the path forward isn’t exactly straight—or maybe it just feels that way when you’re staring at the filings.